355 related articles for article (PubMed ID: 27189167)
1. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.
Jin C; Fotaki G; Ramachandran M; Nilsson B; Essand M; Yu D
EMBO Mol Med; 2016 Jul; 8(7):702-11. PubMed ID: 27189167
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Nonviral
Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
Front Immunol; 2021; 12():802705. PubMed ID: 35082789
[TBL] [Abstract][Full Text] [Related]
3. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
Monjezi R; Miskey C; Gogishvili T; Schleef M; Schmeer M; Einsele H; Ivics Z; Hudecek M
Leukemia; 2017 Jan; 31(1):186-194. PubMed ID: 27491640
[TBL] [Abstract][Full Text] [Related]
4. Non-integrating lentiviral vectors based on the minimal S/MAR sequence retain transgene expression in dividing cells.
Xu Z; Chen F; Zhang L; Lu J; Xu P; Liu G; Xie X; Mu W; Wang Y; Liu D
Sci China Life Sci; 2016 Oct; 59(10):1024-1033. PubMed ID: 27614752
[TBL] [Abstract][Full Text] [Related]
5. Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.
Cheng C; Tang N; Li J; Cao S; Zhang T; Wei X; Wang H
J Med Genet; 2019 Jan; 56(1):10-17. PubMed ID: 30030293
[TBL] [Abstract][Full Text] [Related]
6. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced leukemia in mice with mRNA engineered T cells.
Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
[TBL] [Abstract][Full Text] [Related]
8. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
9. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K
Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
Rivière I; Sadelain M
Mol Ther; 2017 May; 25(5):1117-1124. PubMed ID: 28456379
[TBL] [Abstract][Full Text] [Related]
11. Simplified process for the production of anti-CD19-CAR-engineered T cells.
Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
[TBL] [Abstract][Full Text] [Related]
12. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
13. Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering.
Odak A; Yuan H; Feucht J; Cantu VA; Mansilla-Soto J; Kogel F; Eyquem J; Everett J; Bushman FD; Leslie CS; Sadelain M
Blood; 2023 Jun; 141(22):2698-2712. PubMed ID: 36745870
[TBL] [Abstract][Full Text] [Related]
14. S/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection.
Verghese SC; Goloviznina NA; Skinner AM; Lipps HJ; Kurre P
Nucleic Acids Res; 2014 Apr; 42(7):e53. PubMed ID: 24474068
[TBL] [Abstract][Full Text] [Related]
15. Transiently redirected T cells for adoptive transfer.
Almåsbak H; Rian E; Hoel HJ; Pulè M; Wälchli S; Kvalheim G; Gaudernack G; Rasmussen AM
Cytotherapy; 2011 May; 13(5):629-40. PubMed ID: 21174490
[TBL] [Abstract][Full Text] [Related]
16. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
17. An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency.
Lufino MM; Manservigi R; Wade-Martins R
Nucleic Acids Res; 2007; 35(15):e98. PubMed ID: 17675302
[TBL] [Abstract][Full Text] [Related]
18. Engineered T cell therapies.
Field AC; Qasim W
Expert Rev Mol Med; 2015 Nov; 17():e19. PubMed ID: 26530808
[TBL] [Abstract][Full Text] [Related]
19. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.
Choi Y; Yuen C; Maiti SN; Olivares S; Gibbons H; Huls H; Raphael R; Killian TC; Stark DJ; Lee DA; Torikai H; Monticello D; Kelly SS; Kebriaei P; Champlin RE; Biswal SL; Cooper LJ
Biomed Microdevices; 2010 Oct; 12(5):855-63. PubMed ID: 20574820
[TBL] [Abstract][Full Text] [Related]
20. Episomal lentiviral vectors confer erythropoietin expression in dividing cells.
Chen F; Qi X; Zhang R; Wu ZY; Yan CE; Li J; Liu QY; Qi J
Plasmid; 2017 Mar; 90():15-19. PubMed ID: 28189631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
